{
    "2021-10-29": [
        [
            {
                "time": "2023-10-15",
                "original_text": "CEO details plan for gene therapy firm's $125M RTP expansion",
                "features": {
                    "keywords": [
                        "CEO",
                        "gene therapy",
                        "firm's",
                        "$125M",
                        "RTP expansion"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-16",
                "original_text": "Top Research Reports for Alphabet, Eli Lilly & Sony",
                "features": {
                    "keywords": [
                        "Research Reports",
                        "Alphabet",
                        "Eli Lilly",
                        "Sony"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology",
                        "healthcare",
                        "consumer electronics"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-17",
                "original_text": "Pharma Stock Roundup: Big Pharma Q3 Results, FDA Panel's Vote for PFE COVID Jab",
                "features": {
                    "keywords": [
                        "Pharma Stock",
                        "Big Pharma",
                        "Q3 Results",
                        "FDA Panel",
                        "PFE",
                        "COVID Jab"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "Why Eli Lilly and Company (NYSE:LLY) may be Cheap and has Growth Driven by Capital Investments",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Cheap",
                        "Growth",
                        "Capital Investments"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}